MedTrace Logo

RBL001/RBL002 Phase I Clinical Trial

NCT01684241 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2020-01-18

No results posted yet for this study

Summary

Clinical first-in-human dose escalation study evaluating the safety and tolerability of intranodal administration of an RNA-based cancer vaccine targeting two tumor-associated antigens in patients with advanced melanoma

Conditions

Interventions

BIOLOGICAL

RBL001/RBL002

Each participant will receive 8 repeated intranodal administrations of RBL001 and RBL002 during a time frame of 43 to 51 days.

Sponsors & Collaborators

  • BioNTech RNA Pharmaceuticals GmbH

    lead INDUSTRY

Principal Investigators

  • Ugur Sahin, Prof. Dr. · Ribological GmbH

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2015-05-31
Completion
2015-07-31

Countries

  • Austria
  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01684241 on ClinicalTrials.gov